Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 142 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluzone High Dose Vaccine Clear all

Conditions: Aging Frailty
Interventions: Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions: ExPEC9V, Placebo, HD quadrivalent influenza vaccine; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more

Conditions: Pandemic Influenza
Interventions: A/H5N1, Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 501 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Vallejo, California • Miami, Florida • Kansas City, Kansas + 2 more

Conditions: Pediatric Patients With Acute Lymphoblastic Leukemia
Interventions: High-dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 3 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza
Interventions: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more

Conditions: Influenza
Interventions: High-Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Idaho Falls, Idaho • Columbia, Maryland • Ellicott City, Maryland + 2 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 99 Years
Enrollment: 517 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 5 more

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years and older
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 5
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Influenza
Interventions: HD Fluzone Vaccine, SD Fluzone Vaccine; Biological
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 2,957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Providence, Rhode Island • Norfolk, Virginia

Conditions: Infectious Diseases, Influenza, Avian Flu
Interventions: H5N1 vaccine, Apheresis; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: VXA-A1.1 Oral Vaccine, VXA Placebo Tablet; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Rheumatoid Arthritis
Interventions: Influenza vaccine; Biological
Lead sponsor: Bassett Healthcare; Other
Eligibility: 40 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Pandemic Influenza Immunization, Healthy Volunteers
Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more

Conditions: Refractory and/or Relapsed Metastatic Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • The Bronx, New York • Valhalla, New York

Conditions: Pediatric Solid Organ Transplant Patients
Interventions: High-Dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 3 Years to 17 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza
Interventions: QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 2,670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 36
States / cities: Anaheim, California • Redding, California • San Diego, California + 29 more

Conditions: H1N1 Flu
Interventions: HAC1 Vaccine; Biological
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions: Fluzone High Dose Vaccine, Standard of care/Placebo; Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Human Influenza
Interventions: Standard dose influenza vaccination, High dose influenza vaccination; Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more

Conditions: Pandemic H5N1 Influenza
Interventions: Adjuvanted H5N1 pandemic influenza vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 979 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • St Louis, Missouri • Austin, Texas

Conditions: Healthy Participants
Interventions: Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo; Biological · Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 49 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Search by objective public record fields.

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

A/H5N1 Dose Ranging Study With Adjuvant Patch

Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

H5N1 (Clade 2) Vaccination of Adults and Elderly

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

Eldery High Dose TIV 2005

High Dose Influenza Vaccine in Nursing Home - Pilot Study

Development of Immune Globulin Treatment for Avian Flu

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Duration of Immune Response to Influenza Vaccination in Patients With RA

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Study of the Safety and Immunogenicity of H1N1 Vaccine

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

Tfh Dysfunction in HIV and Aging

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)